159 related articles for article (PubMed ID: 37813018)
1. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context.
Hyun JW; Park NY; Kim MJ; Kim H; Kim KH; Kim SH; Kim HJ
J Neurol Sci; 2023 Nov; 454():120825. PubMed ID: 37813018
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
[TBL] [Abstract][Full Text] [Related]
3. Investigating paraneoplastic aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder through a data-driven approach.
Dinoto A; Borin GU; Campana G; Carta S; Ferrari S; Mariotto S
Eur J Neurol; 2022 Nov; 29(11):3466-3472. PubMed ID: 35767391
[TBL] [Abstract][Full Text] [Related]
4. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
5. AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review.
Apiraksattayakul N; Songwisit S; Owattanapanich W; Tisavipat N; Siritho S; Prayoonwiwat N; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Dec; 68():104212. PubMed ID: 36242805
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
7. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis.
Rocchi C; Forcadela M; Kelly P; Linaker S; Gibbons E; Bhojak M; Jacob A; Hamid S; Huda S
Mult Scler; 2024 Mar; 30(3):345-356. PubMed ID: 38258822
[TBL] [Abstract][Full Text] [Related]
8. Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.
Guerra H; Pittock SJ; Moder KG; Fryer JP; Gadoth A; Flanagan EP
Mayo Clin Proc; 2018 Sep; 93(9):1299-1304. PubMed ID: 29655487
[TBL] [Abstract][Full Text] [Related]
9. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
[TBL] [Abstract][Full Text] [Related]
10. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
Iorio R; Rindi G; Erra C; Damato V; Ferilli M; Sabatelli M
Mult Scler; 2015 May; 21(6):791-4. PubMed ID: 25716881
[TBL] [Abstract][Full Text] [Related]
14. Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.
Edgar Patricio CD; Eleanor THG; Francisco José CZ; Gabriela ACM; Hyland AO; Fernando GL; María TA; Beatriz N; Marcos SD; Alfredo GPW
Mult Scler Relat Disord; 2020 Sep; 44():102208. PubMed ID: 32562910
[TBL] [Abstract][Full Text] [Related]
15. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.
Martín-Nares E; Hernandez-Molina G; Fragoso-Loyo H
Lupus; 2019 Oct; 28(11):1302-1311. PubMed ID: 31566079
[TBL] [Abstract][Full Text] [Related]
16. The temporal relationship of paraneoplastic aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and breast cancer: a systematic review and meta-analysis.
Srichawla BS; Doshi K; Cheraghi SN; Sivakumar S
Neurol Sci; 2023 Nov; 44(11):3809-3817. PubMed ID: 37453952
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature.
Cai G; He D; Chu L; Dai Q; Xu Z; Zhang Y
Int J Neurosci; 2016; 126(7):660-8. PubMed ID: 26010208
[TBL] [Abstract][Full Text] [Related]
18. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
19. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
Rajput HM; Hassan M; Badshah M
Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
[TBL] [Abstract][Full Text] [Related]
20. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]